Request Trial
360b-shutterstock-com-13
360b / Shutterstock.com
2 October 2015Big Pharma

CIPA Congress 2015: GSK will decide on ‘case-by-case’ basis which patents to opt into UPC

Representatives from the pharmaceutical and engineering industries have said that the decision to opt existing patents into the Unified Patent Court (UPC) will be a strategic decision done on a case-by-case basis.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
The clinical trial dilemma: Navigating European practice
27 November 2025   Clinical trials create a patent paradox. With EPO case law rapidly reshaping the 'expectation of success' test—most recently T136/24—the line between innovation and obviousness is blurred. Amanda Simons of J A Kemp offers drafting strategies to secure protection for your downstream innovations.
Big Pharma
Report reveals surge of AI adoption in IP but lawyers remain cautious
20 November 2025   A new report from Clarivate highlights a jump in the tech’s adoption among IP professionals over the past two years, as well as concerns over governance.
Big Pharma
Sun Pharma and BMS lead 2025 ANDA litigation
10 November 2025   According to new research, generic and brand-name pharma companies are ramping up ANDA litigation with Sun Pharma and Bristol Myers Squibb leading the charge.


Editor's picks

The quantum advantage: IP considerations for the next generation of life sciences innovation
Americas
The quantum advantage: IP considerations for the next generation of life sciences innovation
27 January 2026

Editor's picks

Americas
The quantum advantage: IP considerations for the next generation of life sciences innovation
27 January 2026
Americas
Bayer enters COVID-19 vaccine row with three suits against major drugmakers
8 January 2026
Americas
SCOTUS shuts the door on Entresto ‘after-arising technology’ review
17 December 2025
Europe
Abbott appeals ‘baffling’ decision in glucose monitoring device feud
16 December 2025
Americas
Teva scrubs 200-plus Orange Book patents after FTC turns the screw
11 December 2025
Americas
US govt backs Hikma over ‘skinny label’ rules
9 December 2025

More features

LSPN Awards USA returns for second year—with new categories
Drowning in EU regulations? Five tips for surviving the deluge of new rules
Moderna VP and regulatory expert moves to private practice
Crowell adds tech partner with in-house and private practice expertise
Winston & Strawn and Taylor Wessing UK seal ‘powerhouse’ merger
Pearce IP grows practice with senior patent hire
Sanofi suffers setback in insulin monopoly dispute
Firm adds seven-lawyer team in second major merger